BERKELEY, Calif.--(BUSINESS WIRE)--Dynavax Technologies Corporation (Nasdaq: DVAX), a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious diseases, today announced that Deborah A. Smeltzer, Vice President, Operations and Chief Financial Officer, is planning to retire by year-end.
